AFT Pharmaceuticals (NZSE:AFT) Enterprise Value : NZ$321.8 Mil (As of Dec. 15, 2024)

AFT Pharmaceuticals Enterprise Value Chart

AFT Pharmaceuticals Annual Data
	Trend	Mar16	Mar17	Mar18	Mar19	Mar20	Mar21	Mar22	Mar23	Mar24
Enterprise Value		Get a 7-Day Free Trial				391.39	556.70	410.52	396.14	348.38

AFT Pharmaceuticals Semi-Annual Data
	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23	Mar24	Sep24
Enterprise Value	Get a 7-Day Free Trial													337.26	396.14	391.19	348.38	361.40

Competitive Comparison of AFT Pharmaceuticals's Enterprise Value

For the Drug Manufacturers - Specialty & Generic subindustry, AFT Pharmaceuticals's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AFT Pharmaceuticals's Enterprise Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AFT Pharmaceuticals's Enterprise Value distribution charts can be found below:

* The bar in red indicates where AFT Pharmaceuticals's Enterprise Value falls into.

AFT Pharmaceuticals Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

AFT Pharmaceuticals's Enterprise Value for the fiscal year that ended in Mar. 2024 is calculated as

AFT Pharmaceuticals's Enterprise Value for the quarter that ended in Sep. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AFT Pharmaceuticals  (NZSE:AFT) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

AFT Pharmaceuticals's EV-to-EBIT for today is

AFT Pharmaceuticals's current Enterprise Value is NZ$321.8 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. AFT Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 was NZ$20.4 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

AFT Pharmaceuticals's EV-to-EBITDA for today is:

AFT Pharmaceuticals's current Enterprise Value is NZ$321.8 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. AFT Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Sep. 2024 was NZ$22.7 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

AFT Pharmaceuticals's EV-to-Revenue for today is:

AFT Pharmaceuticals's current Enterprise Value is NZ$321.8 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. AFT Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Sep. 2024 was NZ$196.8 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AFT Pharmaceuticals Enterprise Value Related Terms

Thank you for viewing the detailed overview of AFT Pharmaceuticals's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.

AFT Pharmaceuticals Business Description